Strategic Focus Target hospitals and health care providers with a focus on diagnostic testing and GI indications, emphasizing WATS3D capabilities for Barrett's esophagus detection and surveillance to align with CDx Diagnostics expertise.

Technology Leverage Highlight integration capabilities with existing lab and EMR workflows using CDx Diagnostics' WATS3D data outputs, and underscore analytics and AI-assisted pathologist collaboration to improve diagnostic accuracy and throughput.

Clinical Validation Position opportunities around recent DDW data presentations and ongoing enhancements to the WATS3D test to demonstrate clinical utility, potential improvements in early cancer detection, and favorable cost-benefit profiles.

Partnership Potential Explore collaborations with midsize and large reference labs and pathology networks that resemble ARUP, NeoGenomics, or Labcorp in scale, to accelerate adoption through established distribution and service models.

Growth Signals Leverage current funding and leadership momentum to present CDx Diagnostics as a growing innovator in GI cancer screening, presenting case studies and health economics data to procurement teams seeking value-based diagnostics.